
InVivo Therapeutics Holdings Corp. NVIV
Quarterly report 2023-Q3
added 11-08-2023
InVivo Therapeutics Holdings Corp. Depreciation & Amortization 2011-2026 | NVIV
Annual Depreciation & Amortization InVivo Therapeutics Holdings Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 K | 44 K | 46 K | 57 K | 91 K | 395 K | 548 K | 684 K | 752 K | 740 K | 367 K | 145 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 752 K | 44 K | 327 K |
Quarterly Depreciation & Amortization InVivo Therapeutics Holdings Corp.
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 K | 10 K | 19 K | - | 14 K | 13 K | 13 K | - | 35 K | 26 K | 14 K | - | 32 K | 23 K | 11 K | - | 44 K | 32 K | 16 K | - | 75 K | 58 K | 40 K | - | 387 K | 264 K | 135 K | - | 417 K | 284 K | 146 K | - | 527 K | 352 K | 178 K | - | 568 K | 378 K | 195 K | - | 545 K | 353 K | 167 K | - | 219 K | 96.8 K | 42.6 K | - | 102 K | 62.6 K | 28 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 568 K | 4 K | 152 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Compugen Ltd.
CGEN
|
461 K | $ 2.59 | -5.31 % | $ 242 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Aptorum Group Limited
APM
|
1.13 M | $ 0.91 | 3.25 % | $ 6.69 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.57 | -0.44 % | $ 3.74 B | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
487 K | - | 17.91 % | $ 11.1 M | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
Innoviva
INVA
|
26.3 M | $ 23.2 | -2.08 % | $ 1.56 B | ||
|
Aquestive Therapeutics
AQST
|
548 K | $ 4.06 | -0.73 % | $ 434 M | ||
|
Jaguar Health
JAGX
|
1.91 M | $ 0.23 | -5.44 % | $ 536 K | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 22.63 | -2.86 % | $ 2.88 B | ||
|
KalVista Pharmaceuticals
KALV
|
969 K | $ 26.73 | 38.9 % | $ 1.44 B | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.42 | -4.39 % | $ 378 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 2.95 | 1.37 % | $ 4.86 M |